Celyad Oncology to Announce Full Year 2020 Financial Results and Host Conference Call

Rhea-AI Summary

Celyad Oncology will announce its full year 2020 financial results on March 24, 2021. A conference call for discussion will take place on March 25 at 1 p.m. CET / 8 a.m. ET. The company focuses on developing chimeric antigen receptor T cell (CAR T) therapies for cancer, including allogeneic and autologous candidates targeting hematological malignancies and solid tumors. Celyad has received funding from the Walloon Region to support its CAR T programs. The company warns that known and unknown risks may impact its financial condition and business outlook.

Positive

• None.

Negative

• Company has unknown risks that could materially affect financial condition and performance.
• Phase 1 trial initiation was expected by year-end 2020 but may face uncertainties.
• COVID-19 pandemic and government measures pose risks to development timelines.

MONT-SAINT-GUIBERT, Belgium, March 18, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report full year 2020 financial and operating results on the evening of Wednesday, March 24^th.

Following the press release, Celyad management will host a conference call on Thursday, March 25 at 1 p.m. CET / 8 a.m. ET to discuss full year 2020 results and provide an update on the Company’s recent progress and upcoming milestones.

Participants may access the conference call by dialing +1 201 493 6784 (International), +1 877 407 9208 (United States) or +32 (0) 800 735 66 (Belgium). The conference ID for the call is 13716700.

To access the live webcast and archived recording, visit the "Events" section of the Celyad website.

About Celyad Oncology

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.

Forward-Looking Statement

This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the safety and clinical activity of Celyad Oncology’s pipelines and financial condition, results of operation and business outlook. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty includes the expected date of the Phase 1 trial initiation by year-end 2020, our development of additional shRNA-based allogenic candidates from our CYAD-200 series towards clinical trial, and the duration and severity of the COVID-19 pandemic and government measures implemented in response thereto. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on March 25, 2020 and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

Investor and Media Contacts:

Sara Zelkovic
Communications & Investor Relations Director
Celyad Oncology
investors@celyad.com

Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

Source: Celyad Oncology SA

FAQ

When will Celyad report its full year 2020 financial results?

Celyad will announce its full year 2020 financial results on March 24, 2021.

What is the date of the Celyad conference call to discuss financial results?

The conference call will be held on March 25, 2021, at 1 p.m. CET / 8 a.m. ET.

What therapies is Celyad Oncology focused on developing?

Celyad is focused on developing chimeric antigen receptor T cell (CAR T) therapies for cancer.

What risks does Celyad Oncology face according to the press release?

Celyad faces risks that may impact its financial condition and business outlook, including uncertainties related to trial timelines and the COVID-19 pandemic.